Hemorrhoids - Pipeline Insight, 2024

This “Hemorrhoids- Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Hemorrhoids pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Hemorrhoids Understanding

Hemorrhoids: Overview

Hemorrhoids, also called piles, are swollen and inflamed veins around the anus or in lower rectum. External hemorrhoids form under the skin around the anus. Internal hemorrhoids form in the lining of the anus and lower rectum. Symptoms of hemorrhoids depend on the type of hemorrhoid. External hemorrhoid symptoms include anal itching. Internal hemorrhoid symptoms include rectal bleeding. Certain toilet habits, constipation, a low-fiber diet, and aging may cause hemorrhoids.

Hemorrhoids - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hemorrhoids pipeline landscape is provided which includes the disease overview and Hemorrhoids treatment guidelines. The assessment part of the report embraces, in depth Hemorrhoids commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hemorrhoids collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Hemorrhoids R&D. The therapies under development are focused on novel approaches to treat/improve Hemorrhoids.

Hemorrhoids Emerging Drugs Chapters

This segment of the Hemorrhoids report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hemorrhoids Emerging Drugs

CITI-002: Citius Pharmaceuticals CITI-002 is a topical formulation of halobetasol and lidocaine that is intended to provide anti-inflammatory and anesthetic relief to individuals suffering from hemorrhoids. Citius’ halobetasol and lidocaine formulation could become the first FDA-approved product to treat hemorrhoids in the United States.

Hemorrhoids: Therapeutic Assessment

This segment of the report provides insights about the different Hemorrhoids drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Hemorrhoids

There are approx. 10+ key companies which are developing the therapies for Hemorrhoids. The companies which have their Hemorrhoids drug candidates in the most advanced stage, i.e. Phase II include, Citius Pharmaceuticals.

Phases

This report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Hemorrhoids pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hemorrhoids: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Hemorrhoids therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hemorrhoids drugs.

Hemorrhoids Report Insights

• Hemorrhoids Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Hemorrhoids Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Hemorrhoids drugs?
• How many Hemorrhoids drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hemorrhoids?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Hemorrhoids therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hemorrhoids and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Pacira Pharmaceuticals, Inc
• Peritech Pharma Ltd.
• Ventrus Biosciences, Inc
• Nivagen Pharmaceuticals Inc.
• Citius Pharmaceuticals, Inc.
• Panacea Biotec Ltd

Key Products

• SKY0402
• PP110 Gel
• Iferanserin
• Hydrocortisone Acetate Suppository, 25 mg
• Hydrocortisone acetate and lidocaine hydrochloride
• Euphorbia tablets

This product will be delivered within 2 business days.